You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
南新制藥(688189.SH):2024年淨虧損3.54億元
格隆匯 02-27 18:59

格隆匯2月27日丨南新制藥(688189.SH)公佈2024年度業績快報,報告期內,公司生產經營活動正常。截至2024年12月31日,公司總資產123,373.35萬元,比上年同期減少29.00%;歸屬於母公司的所有者權益95,387.82萬元,比上年同期減少27.63%;歸屬於母公司所有者的每股淨資產3.4762元,比上年同期減少27.63%。報告期內,公司實現營業收入27,398.33萬元,比上年同期減少63.20%;實現營業利潤-39,189.22萬元,實現利潤總額-39,246.55萬元,實現歸屬於母公司所有者的淨利潤-35,423.77萬元。

報告期內,由於主營業務受行業政策環境、市場競爭加劇等因素影響,公司及時調整和優化銷售策略,對部分核心產品的銷售價格進行下調,加之2024年第二、三、四季度流感病例較少,導致公司營業收入和毛利率下降。報告期內,公司根據《企業會計準則》及公司會計政策等相關規定,基於謹慎性原則,繼續對各類資產計提資產減值損失及信用減值損失等。報告期內,公司非經常性損益事項影響較少。基於以上因素等,公司經營業績發生虧損。報告期內,公司持續推進降本增效等多項舉措並取得良好的效果,銷售費用、管理費用和財務費用等期間費用均較上年同期呈現明顯的下降。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account